The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / TNF Blocking Drugs Persist in Infants after Exposure In-Utero

TNF Blocking Drugs Persist in Infants after Exposure In-Utero

May 15, 2016 • By Anne Harding

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Babies born to mothers who took anti-tumor necrosis factor (anti-TNF) agents during pregnancy have detectable drug in their bodies up to 12 months of age, new findings show.

You Might Also Like
  • Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections
  • Adalimumab & Infliximab Remain in Newborns after Delivery
  • TNFi Exposure in Utero

These infants should therefore not receive live vaccines during their first year of life, Dr. Mette Julsgaard of Aarhus University Hospital in Denmark and her colleagues conclude in a report online April 7 in Gastroenterology.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Many women with inflammatory bowel disease (IBD) require treatment with anti-TNF drugs during pregnancy, Dr. Julsgaard and her team note. They add that although studies have so far not linked in-utero exposure to adverse neonatal outcomes, there is little data on how infants clear the drug and whether exposure may affect childhood development.

To investigate, the researchers looked at 80 mother-baby pairs from Denmark, Australia and New Zealand. Thirty-six of the mothers received adalimumab during pregnancy, 44 infliximab and 39 also received thiopurines.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Median duration of anti-TNF treatment was 2.5 years. Women on adalimumab received their last pregnancy dose at median gestational week (GW) 35, while the last dose of infliximab was given at median GW 30. Thirty-eight women had a disease relapse while pregnant, while 42 remained in remission.

Cord blood concentrations of anti-TNF agents were higher than maternal concentrations, with a median ratio of infant to maternal concentration at birth of 1.21 for adalimumab and 1.97 for infliximab. Both maternal and cord blood concentrations were inversely correlated with duration since last exposure.

Eight of the babies exposed to adalimumab (22%) had no detectable level of the drug in their cord blood, while infliximab was detected at birth in all of the exposed infants. Mean time to clearance was four months with adalimumab and 7.3 months with infliximab. One infant had detectable levels of infliximab at 12 months, which were cleared by age 15 months.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Four infants developed bacterial infections during their first year, while 16 had viral infections, all of which had benign courses. The relative risk of any infection was 2.7 for infants born to mothers who received both an anti-TNF agent and thiopurine, compared with those on anti-TNF monotherapy.

“It is reassuring that all infant infections had a benign course. Still, combination therapy in pregnant women should be carefully counterbalanced between risk of disease activity in pregnancy (if thiopurine is discontinued) and thereby increased risk of adverse pregnancy outcome such as preterm birth and small for gestational age, and an increased risk of infection in the offspring if combination therapy is continued,” Dr. Julsgaard tells Reuters Health via e-mail. “Therefore pregnant women on combination therapy should receive thorough counseling.”

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, anti-TNF agent, infliximab, pregnancy, TNF

You Might Also Like:
  • Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections
  • Adalimumab & Infliximab Remain in Newborns after Delivery
  • TNFi Exposure in Utero
  • Reinitiating TNF Blockers after Tuberculosis Treatment

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)